Dasatinib Holiday for Improved Tolerability

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2016
Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))
Epistemonikos ID: 57f4f892c7d67271174b34b84b0782ce846a955c
First added on: Jan 21, 2022